X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bdenza (enzalutamide) is a small molecule AR inhibitor available in oral solution form, which is approved for the treatment of patients with prostate cancer.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Bdenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Under the agreement, Procaps will be responsible for registration, branding, marketing and commercialization of 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Procaps Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 07, 2023
Details:
APATIDE (generic version of Apalutamide) is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain and blocks AR nuclear translocation or binding to androgen response elements. Product has been launched in India to treat prostate cancer.
Lead Product(s): Apalutamide
Therapeutic Area: Oncology Product Name: Apatide
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
BDR Pharma elevates its own standard of the wide range of critical care segment products with launch of biapenem under brand name Biapen to treat intra-abdominal, lower respiratory or complicated urinary tract infections, which will be available in the market shortly.
Lead Product(s): Biapenem
Therapeutic Area: Infections and Infectious Diseases Product Name: Biapen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2021
Details:
Cabozantinib is prescribed for treating patients with progressive, metastatic medullary thyroid cancer (MTC) and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2021
Details:
BDR Pharma has inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Indian Defence Research and Development Organisation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2021
Details:
Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3. BDPARIB is first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market.
Lead Product(s): Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: Bdparib
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2021
Details:
Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Lead Product(s): Lenvatinib Mesylate
Therapeutic Area: Oncology Product Name: Bdfoie
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
BDR pharma has received an approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat mild to moderate patients with COVID-19 symptoms. The drug has been launched under the brand name 'BDFAVI.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Bdfavi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
